Company: RCUS
Filing Date: 2025-10-28
Form Type: 10-Q
Source: 0001724521-25-000116
Chunk: 267

Company: Arcus Biosciences, Inc.
Filing Date: 2025-10-28
Form: 10-Q
Item: Part I, Item 8
Chunk 267
---
 Taiho's exercise of its option for quemliclustat in the third quarter 2024. The overall decrease was partially offset by the cumulative catch-up of $143 million in the second quarter 2025 relating to pausing future development of etrumadenant and Gilead's related return of its license to the program, compared to the prior year cumulative catch-up of $107 million as a result of the Third Gilead Collaboration Agreement Amendment in the first quarter 2024.

See Note 5, Revenues, to our Condensed Consolidated Financial Statements in Part I, Item 1 of this report for further discussion of the amount and timing of revenues recognized from our license and collaboration agreements.

Research and Development Expenses

We group all of our R&D activities and the related expenditures into categories as described below:

CategoryDescriptionProgram Level ExpensesKey ClinicalTrialsLate-stage development programsR&D expenses incurred related to a Phase 3 clinical program intended to result in registration of a new product. This includes all unallocated program-level expense not directly attributable to a specific clinical trial once a molecule enters into one or more Phase 3 clinical trials.domvanalimabzimberelimabquemliclustat**casdatifan**ARC-10*STAR-121STAR-221PACIFIC-8PEAK-1PRISM-1Early-stage development and preclinical programsR&D expenses incurred for activities ranging from early-stage development and preclinical to Phase 2 clinical trials. This includes all unallocated program-level expense not directly attributable to a specific clinical trial unless the related program has entered into one or more Phase 3 clinical trials.quemliclustat**casdatifan**etrumadenantAB598AB801ARC-7ARC-8ARC-9ARC-20ARC-25ARC-26*ARC-27EDGE-Lung EDGE-GastriceVOLVESTELLAR-009*VELOCITY-LungVELOCITY-HNSCC***Compensation and personnel costsInternal costs, such as salaries, non-cash stock-based compensation, and other personnel expenses for our R&D employees that are not allocated to specific programs or trials.——Other costsFacilities, depreciation, and other external costs that are not recorded at the investigational product level.——Partnership reimbursementsReimbursements from our collaboration partners for shared costs incurred by us and recognized as a reduction in R&D expense.——

*Study discontinued or completed

**  Quemliclustat moved from early-stage development and